KalVista Pharmaceuticals (KALV) Corporate presentation summary

Mission and strategy

• Focus on developing therapies for rare diseases with high unmet needs, starting with hereditary angioedema (HAE).

• Commercializing EKTERLY, the first and only oral on-demand therapy for HAE in the US and other major markets.

• Strategy includes leveraging global infrastructure to develop, acquire, or in-license additional innovative rare disease therapies.

EKTERLY product overview

• EKTERLY is indicated for acute HAE attacks in patients aged 12 and older, with plans to expand to ages 2-11 by 2027.

• Demonstrates rapid, sustained relief for all HAE attack types and severities, with a strong safety profile.

• Approved in seven major markets: US, EU, UK, Switzerland, Australia, Japan, and Singapore.

HAE disease and treatment landscape

• HAE is a rare disease causing unpredictable, potentially life-threatening swelling attacks, affecting 1 in 35,000–50,000 people globally.

• Treatment guidelines recommend early, universal access to on-demand therapy, but injectable options are underutilized and burdensome.

• Prior to EKTERLY, most patients relied on long-term prophylaxis and injectables, leading to high costs and inadequate control.